Search Results

Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors, announced that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship.

Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors, announced the appointment of Stephen Dowd, PhD, MBA, to its executive team as Chief Business Officer.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds.

Confo Therapeutics announced that it has entered a collaboration agreement with Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.

Confo Therapeutics , a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it will present highlights from the preclinical profiling of CFTX-1554, Confo’s lead clinical candidate in neuropathic pain, during the International Association for the Study of Pain (IASP) 2022 World Congress on Pain, which will take place September 19-23 in Toronto, Canada.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award.

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates.